ORLEANS, ON, June 21, 2019 /CNW Telbec/ - Tetra
Bio-Pharma Inc. ("Tetra" or
the "Corporation") (TSX VENTURE: TBP) (OTCQB: TBPMF), a
global leader in cannabinoid-based drug development and discovery,
is pleased to announce that all matters presented for approval at
the Corporation's annual general and special meeting (the
"Meeting") of shareholders of the Corporation held in
Montréal, province of Québec, on June 20,
2019, were approved.
Election of Directors and Resolutions
All of the nominees listed in Tetra's management information
circular dated May 22, 2019 (the
"Circular") were elected as directors of the Corporation
until the next annual meeting of shareholders or until their
successors are elected or appointed, to the exception of Mr.
Benoit Chotard, whose nomination for
election as director of the Corporation was withdrawn by the
Corporation after he announced his resignation, effective as of
June 14, 2019, as indicated in the
press release issued on June 14,
2019. The results of the vote were as follows:
Nominee
|
|
Votes
For
|
|
%
For
|
|
Votes
Withheld
|
|
%
Withheld
|
Dr. Guy
Chamberland
|
|
19,787,470
|
|
99.68
|
|
64,453
|
|
0.32
|
Dr. W.M. (Bill)
Cheliak
|
|
19,793,048
|
|
99.70
|
|
58,875
|
|
0.30
|
Gregory
Drohan
|
|
19,780,248
|
|
99.64
|
|
71,675
|
|
0.36
|
Carl
Merton
|
|
17,877,431
|
|
90.05
|
|
1,974,492
|
|
9.95
|
The proposal to appoint McGovern, Hurley, Cunningham, LLP as
auditor of the Corporation and to authorize the board of directors
to fix the remuneration to be paid to the auditor, as presented in
the Circular, was approved (99.78%) by the shareholders at the
Meeting.
The amended and restated stock option plan of the Corporation as
described in the Circular was approved (89.92%) by the shareholders
at the Meeting. The amendment provides that the aggregate number of
common shares reserved for the issuance under stock options granted
to insiders, as a group, at any point in time, together with all
the Corporation's previously established and outstanding stock
option plans or grants, will not exceed 10% of the issued common
shares.
The proposed amendment to the articles of incorporation of the
corporation, as fully detailed in the Circular, was also approved
(99.07%) by the shareholders at the Meeting.
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a
biopharmaceutical multifaced corporation with its primary focus in
cannabinoid-based drug discovery and development with a clinical
trial program aimed at bringing novel drugs and treatments to
patients and their healthcare providers. Tetra Bio-Pharma's
subsidiary, Tetra Natural Health, also focuses on the development
and commercialization of natural health and self-care products as
well as the sale of its hemp energy drinks.
For more information visit: www.tetrabiopharma.com and
www.tetranaturalhealth.com
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Forward-looking statements
Some statements in this
release may contain forward-looking information. All statements,
other than of historical fact, that address activities, events or
developments that the Company believes, expects or anticipates will
or may occur in the future (including, without limitation,
statements regarding potential acquisitions and financings) are
forward-looking statements. Forward-looking statements are
generally identifiable by use of the words "may", "will", "should",
"continue", "expect", "anticipate", "estimate", "believe",
"intend", "plan" or "project" or the negative of these words or
other variations on these words or comparable terminology.
Forward-looking statements are subject to a number of risks and
uncertainties, many of which are beyond the Company's ability to
control or predict, that may cause the actual results of the
Company to differ materially from those discussed in the
forward-looking statements. Factors that could cause actual results
or events to differ materially from current expectations include,
among other things, without limitation, the inability of the
Company to obtain sufficient financing to execute the Company's
business plan; competition; regulation and anticipated and
unanticipated costs and delays, the success of the Company's
research and development strategies, including the success of CAUMZ
and its other drug candidates, the applicability of the discoveries
made therein, the successful and timely completion and
uncertainties related to the regulatory process including the
applications for Orphan Drug Designation, the timing of clinical
trials, the timing and outcomes of regulatory or intellectual
property decisions and other risks disclosed in the Company's
public disclosure record on file with the relevant securities
regulatory authorities. Although the Company has attempted to
identify important factors that could cause actual results or
events to differ materially from those described in forward-looking
statements, there may be other factors that cause results or events
not to be as anticipated, estimated or intended. Readers should not
place undue reliance on forward-looking statements. The
forward-looking statements included in this news release are made
as of the date of this news release and the Company does not
undertake an obligation to publicly update such forward-looking
statements to reflect new information, subsequent events or
otherwise unless required by applicable securities
legislation.
SOURCE Tetra Bio-Pharma Inc